Get the Stockscreener App
5.44
1.45%
-0.08
After Hours:
5.43
-0.01
-0.18%
Recursion Pharmaceuticals Inc stock is traded at $5.44, with a volume of 48.11M.
It is down -1.45% in the last 24 hours and down -0.91% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$5.52
Open:
$5.57
24h Volume:
48.11M
Relative Volume:
1.26
Market Cap:
$2.32B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.5097
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-13.65%
1M Performance:
-0.91%
6M Performance:
-4.56%
1Y Performance:
-15.00%
1-Day Range:
$5.33
$5.76
1-Week Range:
$5.33
$6.25
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.44 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research
How to interpret RSI for Recursion Pharmaceuticals Inc. stockTreasury Yields & Proven Capital Preservation Tips - newser.com
Using Bollinger Bands to evaluate Recursion Pharmaceuticals Inc.Recession Risk & Real-Time Stock Price Movement Reports - newser.com
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.July 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Is Recursion Pharmaceuticals Inc. stock poised for growthWeekly Trade Recap & Reliable Breakout Stock Forecasts - newser.com
Will Recursion Pharmaceuticals Inc. stock maintain growth storyQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Biotech Stocks To Add to Your WatchlistOctober 30th - MarketBeat
When is the best time to exit Recursion Pharmaceuticals Inc.July 2025 Review & Long Hold Capital Preservation Plans - newser.com
How Recursion Pharmaceuticals Inc. stock valuations compare to rivalsDollar Strength & Free Reliable Trade Execution Plans - newser.com
Is it time to cut losses on Recursion Pharmaceuticals Inc.July 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Can Recursion Pharmaceuticals Inc. stock hit record highs againStock Surge & Real-Time Market Sentiment Alerts - newser.com
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral
Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat
Best Biotech Stocks To Follow TodayOctober 31st - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative
Signal strength of Recursion Pharmaceuticals Inc. stock in tech scannersGlobal Markets & Free High Return Stock Watch Alerts - newser.com
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
Has Recursion Pharmaceuticals Inc. formed a bullish divergenceVolume Spike & Real-Time Price Movement Reports - newser.com
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fierce Biotech
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline - sharewise.com
How Recursion Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Recursion Pharmaceuticals Incannounces Roche's exercise of option for Microglia MapSEC filing - MarketScreener
Roche Exercises Option with Recursion Pharmaceuticals - TipRanks
Recursion Pharmaceuticals Announces Roche's Option Exercise - TradingView
Published on: 2025-10-29 07:02:21 - newser.com
Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Is Hindustan Media Ventures Limited Stock Poised for a Breakout in YEARVolume Weighted Average Price & Master Stock Selection - earlytimes.in
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - sharewise.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest - simplywall.st
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th - MarketScreener
Recursion (NASDAQ: RXRX) to host Nov 5 (L)earnings call at 8:00 am ET, livestreamed - Stock Titan
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Setups & Smart Investment Allocation Tips - fcp.pa.gov.br
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):